Recruitment and retention of women for clinical leiomyoma trials

Contemporary Clinical Trials

Volumn 31, Issue 1, 2010, Pages 44-48

  McCarthy Keith, Desireé ^a   Nurudeen, Sahadat ^b   Armstrong, Alicia ^a   Levens, Eric ^a   Nieman, Lynnette K ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; Leiomyoma; Recruitment; Retention

Indexed keywords

ASOPRISNIL; FULVESTRANT; GOSERELIN; IRON; LEUPRORELIN; LYNESTRENOL; MIFEPRISTONE; PLACEBO; RALOXIFENE;

ARTICLE; CLINICAL TRIAL; HUMAN; HYSTERECTOMY; MYOMECTOMY; PHYSICIAN; SCREENING; UTERINE ARTERY EMBOLIZATION; UTERUS MYOMA;

FEMALE; HUMANS; LEIOMYOMA; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT DROPOUTS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UTERINE NEOPLASMS;

EID: 73049094039     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2009.09.007     Document Type: Article

References (38)

1. Baird D., Dunson D., Hill M., et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 188 (2003) 100-107
2. Faerstein E., Szklo M., and Rosenshein N.B. Risk factors for uterine leiomyoma: a practice-based case-control study. II. Atherogenic risk factors and potential sources of uterine irritation. Am J Epidemiol 153 (2001) 11-19
3. Wise L.A., Palmer J.R., Stewart E.A., et al. Age-specific incidence rates for self-reported uterine leiomyomata in the Black Women's Health Study. Obstet Gynecol 105 (2005) 563-568
4. Chen C.R., Buck G.M., Courey N.G., et al. Risk factors for uterine fibroids among women undergoing tubal sterilization. Am J Epidemiol 153 (2001) 20-26
5. Buttram V.C., and Reiter R.C. Uterine leiomyomata: etiology, symptomatology and management. Fertil Steril 36 (1981) 433-445
6. Flynn M., Jamison M., Datta S., and Myers E. Health care resource use for uterine fibroid tumors in the United States. Am J Obstet Gynecol 195 (2006) 955-964
7. Fleming I.D. Barriers to clinical trials. Part I: Reimbursement problems. Cancer 74 (1994) 2662-2665
8. Schain W.S. Barriers to clinical trials. Part II: Knowledge and attitudes of potential participants. Cancer 74 (1994) 2666-2671
9. Mansour E.G. Barriers to clinical trials. Part III: Knowledge and attitudes of health care providers. Cancer 74 (1994) 2672-2675
10. Shavers V.L., Lynch C.F., and Burmeister L.F. Knowledge of the Tuskegee study and its impact on the willingness to participate in medical research studies. J Natl Med Assoc 92 (2000) 563-572
11. Powell J.H., Fleming Y., Walker-McGill C.L., and Lenoir M. The project IMPACT experience to date: Increasing minority participation and awareness of clinical trials. J Natl Med Assoc 100 (2008) 178-187
12. Moher D., Schulz K.F., Altman D., and CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 285 (2001) 1987-1991
13. Carbonell Esteve J.L., Acosta R., Heredia B., Perez Y., Castaneda M.C., and Hernandez A.V. Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 112 (2008) 1029-1036
14. Hehenkamp W.J., Volkers N.A., Birnie E., Reekers J.A., and Ankum W.M. Symptomatic uterine fibroids: treatment with uterine artery embolization or hysterectomy-results from the randomized clinical Embolisation versu Hysterectomy (EMMY) Trial. Radiology 246 (2008) 823-832
15. Levens E.D., Blocker W., Armstrong A.Y., et al. CDB-2914 for uterine leiomyomata treatment a randomized controlled trial. Obstet Gynecol 111 (2008) 1129-1136
16. Mara M., Maskova J., Fucikova Z., Kuzel D., Belsan T., and Sosna O. Midterm clinical and first reproductive results of a randomized controlled trial comparing uterine fibroid embolization and myomectomy. Cardiovasc Interv Radiol 31 (2008) 73-85
17. Wilkens J., Chwalisz, Han C., et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab 93 (2008) 4664-4671
18. Chwalisz K., Larsen L., Mattia-Goldberg C., Edmonds A., Elger W., and Winkel C.A. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 87 (2007) 1399-1412
19. Hald K., Klow N.E., Qvigstad E., and Istre O. Laparoscopic occlusion compared with embolization of uterine vessels: a randomized controlled trial. Obstet Gynecol 109 (2007) 20-27
20. Muneyyirci-Delale O., Richard-Davis G., Morris T., and Armstrong J. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial. Clin Ther 29 (2007) 1682-1691
21. Fiscella K.S., Eisinger S.H., Meldrum S., Feng C., Fisher S.G., and Guzick D.S. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol 108 (2006) 1381-1387
22. Mara M., Fucikova Z., Maskova J., Kuzel D., and Haakova L. Uterine fibroid embolization versus myomectomy in women wishing to preserve fertility: preliminary results of a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol 126 (2006) 226-233
23. Donnez J., Hervais Vivancos B., Kudela M., Audebert A., and Jadoul P. A randomized placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomy. Fertil Steril 79 (2003) 1380-1389
24. Palomba S., Russo T., Orio F., et al. Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial. Hum Reprod 17 (2002) 3213-3219
25. Verspyck E., Marpeau L., and Lucas C. Leuproreline depot 3.75 mg versus lynestrenol in the preoperative treatment of symptomatic uterine myomas: a multicentre randomised trial. Eur J Obstet Gynecol Reprod Biol 89 (2000) 7-13
26. Soori G.S., Wilwerding M.B., Carlson J., et al. A prospective study of patient accrual to clinical trials at a NCI-funded community clinical oncology program. J Clin Oncol 26 (2008) Supp; Abstract 9610
27. Ross S., Grant A., Counsell C., et al. Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol 52 (1999) 1143-1156
28. Prescott R.J., Counsell C.E., Gillespie W.J., et al. Factors that limit the quality, number and progress of randomized controlled trials. Health Technol Assess 3 (1999) 1-143
29. Webb M.S., Seigers D., and Wood E.A. Recruiting African American smokers into intervention research: Relationships between recruitment strategies and participant characteristics. Res Nurs Health 32 (2009) 86-95
30. Kiernan M., Phillips K., Fair J.M., and King A.C. Using direct mail to recruit Hispanic adults into a dietary intervention: an experimental study. Annals Behav Med 11 (2000) 89-93
31. Galbreath A.D., Smith B., Wood O., et al. Cumulative recruitment experience in two large single-center randomized, controlled clinical trials. Contemp. Clin. Trials 29 (2008) 335-342
32. Robinson J.L., Fuerch J.H., Winiewicz D.D., et al. Cost-effectiveness of recruitment methods in an obesity prevention trial for young children. Prev Med 44 (2007) 499-503
33. Loftin W.A., Barnett S.K., Bunn P.S., and Sullivan P. Recruitment and retention of rural African Americans in diabetes research: lessons learned. Diabetes Educ 31 (2005) 251-259
34. Johnson R.E., Williams R.D., Nagy M.C., and Fouad M.N. Retention of under-served women in clinical trials: a focus group study. Ethn Dis 13 (2003) 268-278
35. Murthy V.H., Krumholz H.M., and Gross C.P. Participation in cancer clinical trials: race, sex, and age-based disparities. JAMA 291 (2004) 2720-2726
36. Stewart J.H., Bertoni A.G., Staten J.L., et al. Participation in surgical oncology clinical trials: gender, race/ethnigity and age-based disparities. Ann Surg Oncol 14 (2007) 3328-3334
37. Wendler D., Kington R., Madans J., et al. Are racial and ethnic minorities less willing to participate in health research?. PLoS Med 3 (2006) e19
38. Tejada H.A., Green S.B., Trimble E.L., et al. Representation of African-Americans, Hispanics and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst 88 (1996) 812-816